CURRICULUM VITAE

**Date of Revision:** 4/23/2019

**Name:** Irina Esterlis, Ph.D.

**Promoted to:** Associate Professor, Investigator track, Department of Psychiatry

Co-terminous with VACT appointment

**Term:** July 1, 2017 to June 30, 2022

**School**: Yale University School of Medicine

**Education**: B.A. Psychology, SUNY Buffalo, 1999

B.A. Studio Art, SUNY Buffalo, 1999

M.A. Clinical Psychology, University of Connecticut, 2003

Ph.D. Clinical Neuropsychology, University of Connecticut, 2005

**Career/Academic Appointments**

1998-1999 Research Support Specialist, Behavioral Medicine Lab, SUNY Buffalo, NY

2000-2004 Graduate Research Fellow, Department of Psychology, University of Connecticut, Storrs, CT

2004-2005 Intern, Clinical Neuropsychology, Yale University School of Medicine, New Haven CT

2005-2007 Postdoctoral Fellow, Dept. Psychiatry, Yale University School of Medicine, New Haven CT

2007-2008 Postdoctoral Associate, Dept. Psychiatry, Yale University School of Medicine, New Haven CT

2008-2011 Neuropsychologist/Associate Research Scientist, Department of Psychiatry, VACHS and Yale University School of Medicine, New Haven, CT

2011-2017 Assistant Professor, Department of Psychiatry

VACHS and Yale University School of Medicine, New Haven, CT

July 2017 Associate Professor, Department of Psychiatry

VACHS and Yale University School of Medicine, New Haven, CT

**Administrative Positions:**

2008-2012 Supervisor, Human Recruitment in Brain Imaging Program

and the Yale PET Center

2012-present Director, Cognitive Neuroscience and Mood Core, Translational Brain Imaging Program

2013-present Director, Molecular Brain Imaging Program, National Center for PTSD, VACHS

**Board Certification**:

Licensure in Clinical Psychology, 10/10/2008

**Professional Honors or Recognition**:

## International

2019 AAAS media coverage of symposia (Chair)

<https://www.cbsnews.com/news/depression-may-speed-brain-aging-early-research/>

2018-present Member, ACNP

2017-present Member, SfN

2017-present Member, AAAS

2016 NIH, Early Career Reviewer

2014-2017 Associate Member, ACNP

2013 ACNP Travel Award

2012 Basic Science Award

Society for Nuclear Medicine Young Professional Committee

2010-present Member Society for Biological Psychiatry

2010-2015 Member Society for Research on Nicotine and Tobacco

2008 ISBRA/RSA Travel Award

1. CPDD Director’s Travel Award

2003-present Member, International Neuropsychological Society

## National

2008-2010 VA Career Development Award - 1

2008 ICANA Junior Investigator Award

2006 Guze Symposium Travel Award

2000-2003 Member American Psychological Association

1999 Gamma Beta Phi Society

## Regional

2006-2007 Associate Member New York Academy of Sciences

### University

2005-2007 T-32 Research Fellowship, Yale

2000-2004 Research Support Fellowship, UCONN

**Grant History:**

Active Grants

Agency: NIMH

ID#: 1 R01 MH116657-01A1

Title: “In vivo imaging of a neural marker of suicidal behavior in Bipolar Disorder”

PI: Irina Esterlis, Ph.D.

Percent effort: 30%

Direct Costs Per Year: $494,016

Total costs for project period: $4,114,019

Project period: 12/1/18-11/30/23

Agency: Nancy Taylor Foundation

Title: “Evaluation of glutamatergic system in adolescent depression”

P.I. Irina Esterlis, Ph.D.

Percent effort: 5%

Direct costs per year: $108,000

Total costs for project period: $233,280

Project period: 9/2018-9/2020

Agency: NIMH

ID#: [1R01MH104459-01](https://public.era.nih.gov/grantfolder/piAppDetails/genericStatus.do?encryptedParam=_i7RZ4V4Fj0.H5gC-sAh8_VIgJZ-xiQFHgdIeMi5fiZMuvczP08euYQ.) (Esterlis)

Title: “PET-fMRI Study of Glutamate and Frontal Function in Bi- and Uni-polar Depression”

P.I. Irina Esterlis, Ph.D.

Percent effort: 45%

Direct costs per year: $497,241

Total costs for project period: $3,573,873

Project period: 9/2015-5/2020

Agency: VA NCPTSD (Esterlis)

Title: “Paradigm Development to Study Psychiatric Disorders with PET Imaging”

PI: Irina Esterlis, Ph.D.

Percent effort: 5%

Direct Costs Per Year: $150,000

Total costs for project period: $1,500,000

Project period: 4/2012-9/2019

Agency: NIMH

ID#: R21MH112881

Title: “Role of neuroinflammation in the pathophysiology of bipolar depression”

P.I.: Irina Esterlis, Ph.D.

Direct costs per year: $150,000

Total costs for project period: $460,625

Percent effort: 15%

Project period: 4/01/17-3/31/19

Agency: NIMH

ID#: 1R21MH110850-01

Title: “Glutamate Neurotransmission in Bipolar Depression and Mania”

P.I.: Irina Esterlis, Ph.D.   
Direct costs per year: $150,000

Total costs for project period: $460,625

Percent effort: 15%   
Project period: 4/01/17-3/31/19

Agency: NIMH R01MH110674-01A1

Title: “Imaging microglial activation in PTSD with PET”

PI: Cosgrove; Pietrzak

Percent effort: 5%

Direct Costs Per Year: $499,999

Total costs for project period: $4,187,491

Project period: 7/1/17-6/30/22

Role: Co-I

Pending Grants

Agency: NIMH

ID#: 1 R01 MH118728-01A1

Title: “Depression and accelerated brain aging: A PET imaging study”

PI: Irina Esterlis; Robert Pietrzak

Percent effort: 30%

Direct Costs Per Year: $681,948

Total costs for project period: $5,823,510

Project period: 7/1/19-6/30/24

Received 5th percentile. Awaiting Council.

Past Grants

Agency: Nancy Taylor Foundation

Title: “In vivo and postmortem study of synaptic plasticity”

P.I.: Irina Esterlis, Ph.D.

Percent effort: 10%

Direct costs per year: $156,038

Total costs for project period: $500,661

Project period: 9/01/15-8/31/18

Agency: VA NCPTSD (Esterlis, Pietrzak)

Title: “Imaging synaptic density in older veterans with PTSD: a multimodal PET-fMRI study”

PI: Irina Esterlis, Ph.D.

Percent effort: 5%

Direct Costs Per Year: $260,000

Total costs for project period: $260,000

Project period: 12/2016-9/2017

Agency: NIMH

ID#: [1K01MH092681-01A1](https://commons.era.nih.gov/commons/genericStatus.do?actionRole=nonPI&applID=8189931&uhf-token=3kZ6KAJ9lBUt1alhmH5GUyEIASY%3D)

Title: “Role of Beta2-nAChR in Bipolar Disorder”

P.I.: Irina Esterlis, Ph.D.

Percent effort: 50%

Direct costs pear year: $157,858

Total costs for project period: $818,989

Project period: 7/1/11-3/31/17

Agency: NIDA

ID#: 5R01DA15577-6

Title: “Tobacco Smoking, Genes & Nicotinic Receptors”

P.I.: Kelly P. Cosgrove, Ph.D.

Role on project: Co-Investigator

Percent effort: 5%

Totals costs for project period: $1,882,443

Project period: 9/25/08-3/31/16

Agency: Brain & Behavior Research Foundation (Esterlis)

Title: “mGluR5 Availability in Bipolar Disorder”

PI: Irina Esterlis, Ph.D.

Percent effort: 4%

Total costs for project period: $60,000

Project period: 1/15/13-1/14/16

Agency: DANA foundation

Title: “Brain Imaging of the Glutamatergic System in Depression”

P.I.: Irina Esterlis, Ph.D.

Percent effort: 10%

Total costs for project period: $200,000

Project period: 1/1/12-12/31/15

Agency: Nancy Taylor Foundation

Title: “Validation of methods to image ketamine-induced changes in the human brain”

P.I.: Irina Esterlis, Ph.D.

Percent effort: 10%

Total costs for project period: $141,562

Project period: 9/1/13-8/31/2015

Agency: YCCI

Title: “In vivo PET brain imaging of ketamine-induced glutamate release”

P.I.: Irina Esterlis, Ph.D.

Percent effort: 10%

Total costs for project period: $50,000

Project period: 7/1/12-6/30/2014

Agency: WHRY and YCCC

Title: Effect of sex and cigarette smoking on mGluR5 availability

P.I.: Irina Esterlis, Ph.D.

Percent effort: 17%

Total costs for project period: $34,980

Project period: 7/1/12-6/30/2013

Agency: Nancy Taylor Foundation

Title: “mGluR5 imaging in Hepatitis C**”**

P.I.: Irina Esterlis, Ph.D.

Percent effort: 10%

Total costs for project period: $200,000

Project period: 7/1/10-7/31/2013

Agency: NIMH

IND#: 1 R21 MH085198-01A1 (Esterlis)

Title: “Validation of ß2 containing nicotinic acetylcholinergic receptors as a potential therapeutic target in bipolar disorder”

P.I. Irina Esterlis, Ph.D.

Percent effort: 20%

Total costs for project period: $275,000

Project period: 07/16/09 – 10/31/12

Agency: NIDA

ID#: 1 R01 DA022495-01

Title:     "Imaging Nicotinic Acetylcholine Receptors in Schizophrenia"

P.I.: Deepak Cyril D’Souza, M.D.

Percent effort: 10%

Totals costs for project period: $675, 000

Role: Investigator

Project Period: 12/1/08 - 11/30/12

Agency: Dept Vet Affairs

ID#: Career Development Award - 1

Title: “Cognition, Tobacco, and Nicotinic Receptor Occupancy in Schizophrenia”

P.I.: Irina Esterlis, Ph.D.   
Percent effort: 100%   
Total costs for project period: $186,742  
Project period: 7/01/08-9/30/10

# Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale

# International/National

Spring 2020: Invited Speaker at UC Berkley, Integrative Biology: Title TBD

10/2019: Invited Speaker at VCU TCORS: “Imaging the Nicotinic System: The Relation to Psychiatry”

9/2019: Invited Speaker at Toronto University, Department of Psychiatry: “On Neurobiology of PTSD: the Role and Need for Glutamate”

9/2019: Grand Rounds, Invited Speaker at UConn Health Center, Department of Psychiatry: “The glutamatergic metabotropic receptor 5: what is its role in psychiatry?”

9/2019: Grand Rounds, Invited Speaker at Stony Brook University, Department of Psychiatry: “On Neurobiology of PTSD: the Role and Need for Glutamate”

5/2019: Invited Speaker at Indiana University Medical School, Department of Neuroscience, Stark Institute: “The glutamatergic metabotropic receptor 5: what is its role in psychiatry?”

4/2019: Invited Speaker at Columbia University, Department of Psychiatry: “The glutamatergic metabotropic receptor 5: what is its role in psychiatry?”

9/2018: Invited Speaker at UPenn, Department of Psychiatry: “Where Does Glutamate Fit In The Neurobiology of PTSD? Lessons From Animal Models, Human Imaging Studies, And Clinical Trials”

4/2018: Invited Speaker at Florida Psychiatry Society: “Where Does Glutamate Fit In The Neurobiology of PTSD? Lessons From Animal Models, Human Imaging Studies, And Clinical Trials”

11/2017: Invited Speaker at NIMH “Insights from PET imaging studies of stress: questions, answers, and more questions”

3/2017: Invited Speaker at Harvard University, Martino’s Center for Biomedical Imaging “Down with mGluR5, up with synaptic density: Insights from PET studies”

10/2015: Invited Speaker at University of Pittsburgh, Department of Psychiatry “mGluR5 and Depression: Insights from Neuroimaging Studies”

3/2015: Invited Speaker at Stony Brook University, Department of Psychiatry “The Cholinergic Hypothesis of Depression: Revisited with Receptor Imaging”

# 3/2013: Web based CME course/credit based on my manuscript “Effect of a nicotine vaccine on nicotine binding to the beta2-nAChRs in vivo in human tobacco smokers. *Am J Psychiatry.”*

5/2013: Invited Symposium at CCNP conference, Toronto, Ontario “Individual Differences in Tobacco Addiction: Insights from Cognitive, Neuroimaging and Genetic Studies”

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:**

**International/National**

2019: Society for Biological Psychiatry, Chicago, IL: “Differential Effects of Ketamine on Mood Symptoms and Cognitive Function in MDD and PTSD”

2019: Society for Biological Psychiatry, Chicago, IL: “From Inflammation to Circuits - Cells, Synapses and Signaling Pathways in Depression”

2019: American Association for the Advancement of Science, Washington DC. Session Chair and speaker: “Neurology and Psychiatry: Meeting in the Aging Brain”

2018: ACNP, Hollywood FL: “Synapses and Cognition in Aging: Does Depression Accelerate the Decline?”

2018: ACNP, Hollywood FL: “In Vivo Evidence for mGluR5 Dysregulation as a Biomarker of Suicidality in PTSD, but Not MDD”

2018: ACNP, Hollywood FL: “Imaging Alpha7 Nicotinic Acetylcholine Receptors in PTSD: Preliminary Findings and Sex Differences”

2018: ACNP, Hollywood FL: “In-Vivo Alpha-7 Nicotinic Acetylcholine Receptor Availability and Relationship to Cognition in Schizophrenia”

2018: ACNP, Hollywood FL: “In Vivo Evidence of Aberrant Synaptic Plasticity in Cocaine Users Vs. Healthy Controls Using 11C-UCB-J PET”

2018: Neuroreceptor Mapping (NRM), London, UK: “Investigating mGluR5 as a biomarker of suicidality in Bipolar Disorder: in-vivo and post-mortem evidence”

2018: Neuroreceptor Mapping (NRM), London, UK: “Dysregulation of mGluR5 in borderline personality disorder: A Pilot PET Study with [18F]FPEB”

2018: SoBP, NY, NY: “Preliminary evidence for mGluR5 dysregulation in in borderline

personality disorder and relationship to suicidal behavior”

2018: SoBP, NY, NY: “Imaging α7 Nicotinic Acetylcholine Receptors in PTSD”

2018: SoBP, NY, NY: “Preliminary evidence for altered synaptic density and a possible role for accelerated aging in MDD: a [11C]UCB-J PET study “

2018: American Association for the Advancement of Science, Austin, TX “Preliminary in vivo evidence for mGluR5 as a potential biomarker to differentiate Major Depressive Disorder from Bipolar Disorder”

2018: Winter Brain Conference, Whistler, British Columbia, Canada “mGlu5 Receptors at the Intersection of stress, sex and addiction: Tales of Rats and Humans”, panel presentation

2017: American College for Neuropsychopharmacology, Palm Springs, CA “Preliminary in Vivo Evidence for mGluR5 as a Potential Biomarker to Differentiate Major Depressive Disorder From Bipolar Disorder”

2017: Association of Behavioral and Cognitive Therapies, San Diego, CA “Effect of Ketamine Administration on Posttraumatic Cognitions: Preliminary Evidence”

2017: International Summit on Suicide Research, Henderson, Nevada “Preliminary evidence for dysregulation in mGluR5 as a biomarker of suicidal ideation in PTSD: a PET imaging study”

2017: Society for Biological Psychiatry, San Diego, CA, “In Vivo Quantification of mGluR5 Availability in Posttraumatic Stress Disorder”

2017: Society for Biological Psychiatry, San Diego, CA, “In Vivo Evidence of Lower Synaptic Density in Depression and Associated Mood and Cognitive deficits: A [11C]UCB-J Pet Imaging Study”

2016: American College of Neuropsychopharmacology (ACNP), Hollywood, FL, “In Vivo Quantification of Synaptic Density in Depression With 11C-UCB-J PET Brain Imaging”

2016: American College of Neuropsychopharmacology (ACNP), Hollywood, FL, “Prefrontal cortical mGluR5 availability in PTSD: preliminary findings from an [18F]FPEB PET study”

2016: Tobacco Centers of Regulatory Science (TCORS), Bethesda, MD, “Imaging the effect of electronic cigarettes at the beta2-nicotinic acetylcholine receptors”

2016: Neuroreceptor Mapping (NRM), Boston, MA, “A test-retest study of same-day *in vivo* variation of estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB”

2016: NRM, Boston, MA, “Sensitivity of the α4β2\* Nicotinic Acetylcholine Receptor-Specific Radioligand (-)-[18F]Flubatine to Acetylcholine Levels: Comparison of Two-Scan Bolus Injection and Single-Scan Bolus Plus Constant Infusion Paradigms”

2016: NRM, Boston, MA, “Evaluation of the Corpus Callosum as a Reference Region for (-)-[18F]Flubatine”

2015: American College of Neuropsychopharmacology (ACNP), Miami, FL, “Ketamine-induced changes in [11C]ABP688 binding in healthy and depressed human subjects”

2015: BrainPET, Vancouver, CA, “Ketamine-induced changes in [11C]ABP688 binding in healthy and depressed human subjects”

2015: World Congress of Biological Psychiatry (WFSBP), Athens, Greece, “In vivo evidence for β2\*-nAChR upregulation in smokers with schizophrenia”, symposium presenter

2015: Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA, “Genetic Influences by *CHRNA4*, *ANKK1*, and *BDNF* on Beta2-Nicotinic Acetylcholine Receptor Availability in Smokers and Nonsmokers”

2014: NRM, Netherlands, “Imaging ketamine-induced changes using Positron Emission Tomography and [11C]ABP688”

2014: SoBP, New York, NY, “Ketamine-induced changes in [11C]ABP688 binding in healthy and depressed human subject

2013: ACNP, Hollywood, FL, “α4β2-Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation and Therapeutics”, Co-Chair and presenter

2013: ACNP, Hollywood, FL, “Ketamine-induced changes in [11C]ABP688 binding in healthy human subjects

2013: Society for Research on Nicotine and Tobacco, Boston, MA “α4β2-nicotinic acetylcholine receptors in schizophrenia: Implications for comorbid tobacco smoking and therapeutics”, Chair and presenter

2012: ACNP, Hollywood, FL, “Imaging the Sensitivity of [123I]5‐IA‐85380 to Increases in Acetylcholine at the Beta2‐Nicotinic Acetylcholine Receptors: Physostigmine Studies in Human Subjects“

2012: Neuroreceptor Mapping conference, Baltimore, MD “Imaging the Sensitivity of [123I]5‐IA‐85380 to Increases in Acetylcholine at the Beta2‐Nicotinic Acetylcholine Receptors: Physostigmine Studies in Human Subjects”

2012: Neuroreceptor Mapping conference, Baltimore, MD “Effect of a Nicotine Vaccine on Nicotine Binding to the Beta2‐nAChRs In Vivo in Human Tobacco Smokers”

2012: Society for Nuclear Medicine, Miami, FL “Imaging the Sensitivity of [123I]5‐IA‐85380 to Increases in Acetylcholine at the Beta2‐Nicotinic Acetylcholine Receptors: Physostigmine Studies in Human Subjects”

2012: Society for Research on Nicotine and Tobacco, Houston, TX “Effect of a Nicotine Vaccine on Nicotine Binding to the Beta2‐nAChRs In Vivo in Human Tobacco Smokers”

2012: Biological Psychiatry, Philadelphia, PA “Beta2-nicotinic acetylcholinergic receptors in bipolar depression: a SPECT imaging study”

2011: CPDD, Hollywood, FL “Genetic regulation of beta2-nAChR availability in nonsmokers: influence of ANKKI and CHRNA4”

2011: CPDD, Hollywood, FL “Sex Differences in Tobacco Smoking-Induced Upregulation of Beta2-Nicotinic Acetylcholine Receptors: A [123I]5-IA-85380 SPECT Imaging Study”

2011: Society for Research on Nicotine and Tobacco, Toronto, Canada “[Persistent β2\*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.](http://www.ncbi.nlm.nih.gov/pubmed/22772158)”

2011: Society for Research on Nicotine and Tobacco, Toronto, Canada “Genetic regulation of beta2-nAChR availability in nonsmokers: influence of ANKKI and CHRNA4”

2011: APA “Sex Differences in Tobacco Smoking-Induced Upregulation of Beta2-Nicotinic Acetylcholine Receptors: A [123I]5-IA-85380 SPECT Imaging Study”

2010: ACNP, Miami, FL “β2\*-nAChR Receptor Availability is Lower in Recently Abstinent Smokers with Schizophrenia compared to Healthy Smokers”

2010: SRNT, Baltimore, MD “Sex and smoking status mediate GABAA-benzodiazepine receptor availability”

2010: SRNT, Baltimore, MD “β2\*-nAChR Receptor Availability is Lower in Recently Abstinent Smokers with Schizophrenia compared to Healthy Smokers”

2010: SRNT, Baltimore, MD “Beta2\* Nicotinic acetylcholine receptors modulate pain sensitivity in acutely abstinent tobacco smokers”

2009: RSA, San Diego, CA “Preliminary evidence that smoking influences cortical GABAA-BZR availability in long term sober alcohol dependent subjects”

2008: SRNT, Portland, OR “[123-I]5-IA-85380 SPECT imaging Nicotine Occupancy of Brain Beta2 Nicotinic Acetylcholine Receptors After Smoking Low Nicotine and Nicotine-Free Cigarettes”

2008: NRM, Pittsburg, PA “[123-I]5-IA-85380 SPECT imaging Nicotine Occupancy of Brain Beta2 Nicotinic Acetylcholine Receptors After Smoking Low Nicotine and Nicotine-Free Cigarettes”

2008: NRM, Pittsburg, PA “[Persistent β2\*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.](http://www.ncbi.nlm.nih.gov/pubmed/22772158)”

2008: NRM, Pittsburg, PA “[123I]5-IA SPECT imaging of nicotinic acetylcholine receptors in heavy drinking non-smokers.”

2008: ICANA, New Haven, CT “SPECT GABAA-Benzodiazepine Receptor Imaging of Abstinent Alcohol-Dependents”

2007: SRNT Dublin, Ireland “Nicotine occupancy of beta2\*-nAChRs after use of nicotine inhaler: relationship to craving”

2007: SRNT, Dublin, Ireland “Nicotine and tobacco smoke have different effects on cognitive functioning and craving in abstinence cigarette smokers”

2007: CPDD, Scottsdale, AZ “SPECT Imaging of GABAA-BZRs in smokers and non-smokers.“

2006: RSA, Washington, DC “[123I]5-IA SPECT imaging of nicotinic acetylcholine receptors in heavy drinking non-smokers.”

2006: INS, Boston, MA “The relationship of the P300 to cognition in male adolescent sons of substance dependent fathers”

2006: SRNT, Austin, TX “SPECT Imaging of GABAA-BZRs in smokers and non-smokers”

2004: INS, Baltimore, MD “Predicating reported memory loss in post treatment Lyme disease.”

2004: INS, “Age- and short form IQ-adjusted MOANS norms for the TMT, Stroop, and COWAT”

2003: APA, Toronto, Canada “Effectiveness of short relaxation technique in the workplace”

2003: APA, Toronto, Canada “Comparative efficacy of two brief relaxation techniques in the workplace”

2002: APA, San Francisco, CA “Growth from traumatic experiences”

2002: APA, San Francisco, CA “Aspects of religiousness and compliance with diabetes self-care”

**Professional Service**

***Journal Service:***

Editorial Board: Chronic Stress

Reviewer: Biological Psychiatry, Neuroimage, Nicotine and Tobacco Research, Addiction, Pain, Psychiatry Research – Neuroimaging, Neuropsychopharmacology, American Journal of Psychiatry, Molecular Biology, JAMA

***Professional Service for Professional Organizations***

2019-2021 ACNP Program Committee

2017-present ACNP Women’s Task Force

2017-present SoBP Mentoring Committee

2014-present NIH LRP reviewer, NIH special study section reviewer (ETTN L51), NIH R61/R33 study section reviewer, ad hoc reviewer for several section, on Continuous Submission privilege since 2017.

2014-2018 NIH I/START reviewer

2010-2012 SRNT, Abstract reviewer, aided with program selection

**Public Service**

2011-2016: cook for Columbus House Overflow Shelter

2010-2015: Congregation Mishkan Israel nursery school committee

2012: Congregation Mishkan Israel director selection committee

2013-2016: Bear Path Elementary School PTA committee volunteer

2016-present: IRIS refugee resettlement program

2017-present: Guilford Public Schools helping hand

2017-present: Guilford task force for Start School Later initiative

2017-present: CT NCSP South Central Suicide Advisory Coalition

2017-present: Developmental Assets for Youth Coalition

**Bibliography**

Peer-reviewed original research

1. Raynor, H. A., Kilanowski, C. K., **Esterlis, I.**, & Epstein, L. H. (2002). A cost-analysis of adopting a healthy diet in a family-based obesity treatment program. *Journal of the American Dietetics Association, 102,* 645-650. of nondisplaceable binding. *Journal of Nuclear Medicine, 51,* 1226-1233.

2. Ponce, A. N.,Lorber, W., Paul, J., **Esterlis, I.**, Barzvi, A., Allen, G. J., & Pescatello, L. (2008). Comparisons of varying dosages of relaxation in a corporate setting: Effects on stress reduction. *International Journal of Stress Management, 15,* 396-407.

3. KP Cosgrove, JC Batis, F Bois, PK Maciejewski, **I Esterlis,** T Kloczynski, S Stiklus, S Krishnan-Sarin, S O’Malley, E Perry, G Tamagnan, JP Seibyl, and JK Staley. β2-Nicotinic Acetylcholine Receptor Availability during Acute and Prolonged Abstinence from Tobacco Smoking. *Archives of General Psychiatry, 2009.* *66,* 666-76.

4. **Esterlis, I.,** Cosgrove, K.P., Batis, J.C., Bois, F., Kloczynski T.A., Stiklus S.M., Perry, E.B., Tamagnan, G.D., Seibyl, J.P., Makuch, R., Krishnan-Sarin, S, O’Malley, S., and Staley, J.K. (2009). GABAA-benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression*.* *Synapse*, *63*, 1089-1099.

5. **Esterlis, I.**, Cosgrove, K., Petrakis, I., Bois, F., Krantzler, E., Stiklus, S., Perry, E., Tamagnan, G., Seibyl, Krystal, J. H., and Staley, J. (2010). [123I]5-IA SPECT imaging of nicotinic acetylcholine receptors in heavy drinking nonsmokers. *Drug and Alcohol Dependence*, *108,*146-50.

6. Cosgrove, KP, **Esterlis, I,** McKee, S, Bois, F, Alagille, D, Tamagnan, G, Seibyl, JP, Krishnan-Sarin, S, and Staley, JK. (2010) Beta2\*-Nicotinic Acetylcholine Receptors are Involved in Nociception in Acutely Abstinent Tobacco Smokers. *Nicotine and Tobacco Research, 12,* 535-9.

7. **Esterlis, I**, Cosgrove, K.P, Batis, J.C., Bois, F., Stiklus, S.M., Perkins, E., Seibyl, J.P., Carson, R.E., Staley, J.K. (2010). Quantification of smoking induced occupancy of β2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding.  *Journal of Nuclear Medicine, 51,* 1226-1233.

8. **Esterlis, I,** Mitsis, EM, Batis, JC, Bois, F, Picciotto, MR, Stiklus, SM, Kloczynski, T, Perry, E, Seibyl, JP, McKee, S, Staley, JK, and Cosgrove, KP. (2011). Brain β2\*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. *International Journal of Neuropsychopharmacology*, *14,* 389-98.

9. D’Souza, DC, **Esterlis, I,** Carbuto, M, Krasenics, M, Seibyl, J, Bois, F, Pittman, B, Ranganathan, M, Cosgrove, K, Staley, J. (2012). Lower β2\*-Nicotinic Acetylcholine Receptor Availability in Smokers with Schizophrenia. *Am J Psychiatry,* 169, 326-34.

10. **Esterlis, I,** McKee, SA, Kirk, K, Lee, D, Bois, F, Stiklus, SM, Seibyl, JP, Krishnan-Sarin, S, O’Malley, SS, Staley, JK, Cosgrove, KP**.** (2013).Sex-specific differences in GABAA-benzodiazepine receptor availability: Relationship with sensitivity to pain and tobacco smoking craving. *Addiction Biology,* 18, 370-8.

11. Cosgrove, KP, **Esterlis, I,** McKee, SA, Bois, F, Seibyl, JP, Mazure, CM, Krishnan-Sarin, S, Staley, JK, Picciotto, MR, and O’Malley, SS. (2012). Sex differences in availability of β2\*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. *Archives of General Psychiatry,* 69, 418-27.

12. Saricicek A,\* **Esterlis** I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, Chen JI, Cosgrove KP, Kerestes R, Ghose S, Tamminga CA, Pittman B, Bois F, Tamagnan G, Seibyl J, Picciotto MR, Staley JK, Bhagwagar Z. (2012). [Persistent β2\*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder.](http://www.ncbi.nlm.nih.gov/pubmed/22772158) *Am J Psychiatry,* 169, 851-9. \*First author shared.

13. **Esterlis, I,** Hannestad, JO, Bois, F, Sewell, RA, Tyndale, R, Seibyl, JP, Picciotto, MR, Laruelle, M, Carson, RE, Cosgrove, KP. (2013). Imaging changes in synaptic acetylcholine availability in living human subjects. *J Nuc Med.* 54, 78-82.

14. **Esterlis, I**, Hannestad, JO, Perkins, E, Bois, F, D’Souza, DC, Tyndale, RF, Seibyl, JP, Hatsukami, DM, Cosgrove, KP, O’Malley, SS. (2013). Effect of a nicotine vaccine on nicotine binding to the beta2-nAChRs in vivo in human tobacco smokers. *Am J Psychiatry.* 170, 399-407.

15. Hannestad, J., Cosgrove, K.P., DellaGioia, N., Perkins, E., Bois, F., Bhagwagar, Z., Seibyl, J.P., McClure-Begley, T.D., Picciotto, M.R., **Esterlis, I.** (2013). Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5-IA SPECT. *Biological Psychiatry.* 74, 768-76.

16. Hannestad J, Dellagioia N, Gallezot JD, Lim K, Nabulsi N, **Esterlis** I, Pittman B, Lee JY, O'Connor KC, Pelletier D, Carson RE. (2013). [The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study.](http://www.ncbi.nlm.nih.gov/pubmed/23850810) *Brain Behav Immun.* 33, 131-8.

17. **Esterlis** I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, D'Souza DC. (2013). [In Vivo Evidence for β2 Nicotinic Acetylcholine Receptor Subunit Upregulation in Smokers as Compared with Nonsmokers with Schizophrenia.](http://www.ncbi.nlm.nih.gov/pubmed/24360979)

*Biol Psychiatry*. 76, 495-502. PMC4019710

18. DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Wen JYR, Mann JJ, Krystal JH, Parsey RV, Carson RE, **Esterlis I**. (2015). In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptors subtype. *Biological Psychiatry*. 77, 266-75.

19. Gallezot JD, **Esterlis** I, Bois F, Zheng MQ, Lin SF, Kloczynski T, Krystal JH, Huang Y, Sabri O, Carson RE, Cosgrove KP. (2014). [Evaluation of the sensitivity of the novel α4β2\* nicotinic acetylcholine receptor PET radioligand (18) F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys.](http://www.ncbi.nlm.nih.gov/pubmed/25043426) *Synapse.* 68, 556-64.

20. Cosgrove KP, McKay R, **Esterlis I**, Kloczynski T, Perkins E, Bois F, Pittman B, Lancaster J, Glahn DC, O'Malley S, Carson RE, Krystal JH. (2014). Tobacco smoking interferes with GABAA receptor neuroadaptations during prolonged alcohol withdrawal. *Proc Natl Acad Sci.* 111, 18031-6.

21. Bois F, Gallezot JD, Zheng MQ, Lin SF, **Esterlis I**, Cosgrove KP, Carson RE, Huang Y. (2015). Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. *Nucl Med Biol.* 42, 570-7.

22. **Esterlis I**, Hillmer AT, Bois F, Pittman B, McGovern E, O’Malley SS, Picciotto MR, Yang BZ, Gelernter J, Cosgrove KP. (2016). *CHRNA4* and *ANKK1* Polymorphisms Influence Smoking Induced Nicotinic Acetylcholine Receptor Upregulation. *Nic and Tobacco Research.* 18, 1845-52.

23. Hillmer AT, **Esterlis I**, Gallezot JD, Bois F, Zheng MQ, Nabulsi N, Lin SF, Papke RL, Huang Y, Sabri O, Carson RE, Cosgrove KP. (2016) Imaging of cerebral α4β2\* nicotinic acetylcholine receptors with (-)-[18F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. *Neuroimage*. 141, 71-80.

24. McClure-Begley TD, **Esterlis** I, Stone KL, Lam TT, Grady SR, Colangelo CM, Lindstrom JM, Marks MJ, Picciotto MR. (2016).[Evaluation of the Nicotinic Acetylcholine Receptor-Associated Proteome at Baseline and Following Nicotine Exposure in Human and Mouse Cortex.](http://www.ncbi.nlm.nih.gov/pubmed/27559543)*eNeuro*, 3.

25. C DeLorenzo, JD Gallezot, J Gardus, J Yang, B Planeta, N Nabulsi, RT Ogden, DC Labaree, Y Huang, JJ Mann, F Gasparini, X Lin, JA Javitch, RV Parsey, RE Carson, **I Esterlis**. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB. *JCBFM.* 37, 2716-2727.

26. SE Holmes, **I Esterlis**, CM Mazure, YY Lim, D Ames, S Rainey-Smith, RN Martins, O Salvado, V Dore, VL Villemagne, CC Rowe, SM Laws, CL Masters, P Maruff, RH Pietrzak. (2016). Amyloid-Β, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. *Am Journal Geriatric Psych,* 24, 1191-1195.

27. **I Esterlis**, N DellaGioia, R Pietrzak, D Matuskey, N Nabulsi, C Abdallah, J Yang, C Pittenger, G Sanacora, J Krystal, R Parsey, R Carson, and C DeLorenzo. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. *Molecular Psych.* 23, 824-832.

28. Hillmer AT, Li S, Zheng MQ, Scheunemann M, Lin SF, Nabulsi N, Holden D, Pracitto R, Labaree D, Ropchan J, Teodoro R, Deuther-Conrad W, **Esterlis I**, Cosgrove KP, Brust P, Carson RE, Huang Y. (2017). PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. *Eur J Nucl Med Mol Imaging*, 44, 1042-1050

29. Boggs DL, Surti TS, **Esterlis I**, Pittman B, Cosgrove K, Sewell RA, Ranganathan M, D'Souza DC. (2017). Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. *Schizophr Res*. S0920-9964; 30187-1.

30. Baldassarri, SR, Hillmer, AT, Anderson, JM, Jatlow, P, Nabulsi, N, Labaree, D, Cosgrove, KP, O’Malley, SS, Eissenberg, T, Krishnan-Sarin, S, **Esterlis, I.**Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study. *Nicotine and Tobacco Research*. 20, 425-433.

31. Abdallah, CG, Hannestad, J, Mason, GF, Holmes, SE, DellaGioia, N, Sanacora, G, Jiang, L, Matuskey, D, Satodiya, R, Gasparini, F, Lin, X, Javitch, J, Planeta, B, Nabulsi, N, Carson, RE, **Esterlis, I**. mGluR5 and glutamate involvement in MDD: a multimodal imaging study. *Biological Psych: CNN. 2,* 449–456*.*

32. Davis, MT, DellaGiogia, N, Matuskey, D, Harel, B, Pietrzak, R, & **Esterlis, I**. (2017). Preliminary evidence concerning cognitive deficits in individuals with major depressive disorder assessed by Cogstate measures. *Journal of Affective Disorders*, 218, 82-85*.*

33. Holmes, SE, Girgenti, MJ, Davis, MT, Pietrzak, RH, DellaGioia, N, Nabulsi, N, Matuskey, D, Southwick, S, Duman, R, Carson, RE, Krystal, JH, **Esterlis, I,** Traumatic Stress Brain Study Group. Altered metabotropic glutamate receptor 5 markers in PTSD: *in-vivo* and postmortem evidence. *PNAS*. *114,* 8390-8395.

34. Holmes SE, **Esterlis** I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Fowler C, Ellis K, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH, Maruff P; Australian Imaging, Biomarkers and Lifestyle Research Group. (2017). Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. *Int J Geriatr Psychiatry*. 33, 405-413.

35. Scheinost D, Holmes SE, DellaGioia N, Schleifer C, Matuskey D, Hampson M, Krystal JH, Anticevic A, **Esterlis I**. (2018). Multimodal investigation of network level effects using intrinsic functional connectivity, anatomical covariance, and structure-to-function correlations in unmedicated major depressive disorder. *Neuropsychopharmacology*. 43, 1119-1127.

36. Bhatt S, Hillmer AT, Nabulsi N, Matuskey D, Lim K, Lin SF, **Esterlis** I, Carson RE, Huang Y, Cosgrove KP. (2017). Evaluation of (-)-[18F]Flubatine Specific Binding: Implications for Reference Region Approaches. *Synapse*. Epub ahead of print.

37. Holmes SE, Scheinost D, DellaGioia N, Davis M, Matuskey D, Pietrzak R, Hampson M, Krystal J, **Esterlis I** (2018). Cerebellar and prefrontal cortical alterations in PTSD: structural and functional evidence. *Chronic Stress*. Jan-Dec;2.

38. Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury G, Purohit P, de Graaf RA, **Esterlis I**, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF (2018). The Effects of Ketamine on Prefrontal Glutamate Neurotransmission in Healthy and Depressed Subjects. *Neuropsychopharmacology*. 43, 2154-2160.

39. Holmes S, Scheinost D, Finnema S, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Pietrzak R, Duman R, Sanacora G, Krystal J, CarsonR, **Esterlis I**. Lower synaptic density is associated with depression severity and network alterations. *Nature Communications*. 10, 1529.

|  |
| --- |
| 40. Davis MT, Hillmer A, Holmes SE, Pietrzak RH, DellaGiogia N, Nabulsi N, Matuskey N, Angarita GA, Carson RE, Krystal JH, **Esterlis I**. *In vivo* evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. *PNAS*, In press. |

Chapters, Books and Reviews

1. **Esterlis I**, Krishnan-Sarin S, and Staley JK. Neurochemical Substrates of Habitual Tobacco Smoking. (2007). In Drug Abuse Handbook, Second Edition, Ed S.B. Karch CRC Press, New York.

2. Cosgrove KP, **Esterlis I,** Mason GF, Bois F, O'Malley SS, Krystal JH. (2011). [Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence.](http://www.ncbi.nlm.nih.gov/pubmed/21276806) *Neuropharmacology.*

3. Cosgrove KP, **Esterlis I**, Sandiego C, Petrulli R, Morris ED. (2015). Imaging Tobacco Smoking with PET and SPECT. *Curr Top Behav Neurosci.* 1-17.

4. Abdallah CG, AdamsTG, Kelmendi B, **Esterlis I**, Sanacora G, Krystal JH. (2016). Ketamine’s mechanisms of action: a path to rapid-acting antidepressants. *Depress Anxiety.* 33, 689-97.

5. Davis, MT, Holmes, S, Pietrzak, R, & **Esterlis, I**. (2017). Neurobiology of chronic stress related psychiatric disorders: Evidence from molecular imaging studies. *Chronic Stress*. Jan-Dec.

6. **I Esterlis**, SE Holmes, P Sharma, JH Krystal, C DeLorenzo. mGluR5 and Stress Disorders: Knowledge Gained from Receptor Imaging Studies. *Biological Psychiatry*. Epub ahead of print.

Case Reports, Technical Notes, Letters

1. Lane, M., **Esterlis, I.**, Tello, A., Vesga-Lopez, O., Zonana, H., & Jean-Baptiste, M. (2006). Using the Internet for Clinical Information Gathering about Unidentified Psychiatric Patients. *Journal of Psychiatric Practice, 12,* 324-326.